JP6190368B2 - 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 - Google Patents

免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 Download PDF

Info

Publication number
JP6190368B2
JP6190368B2 JP2014531244A JP2014531244A JP6190368B2 JP 6190368 B2 JP6190368 B2 JP 6190368B2 JP 2014531244 A JP2014531244 A JP 2014531244A JP 2014531244 A JP2014531244 A JP 2014531244A JP 6190368 B2 JP6190368 B2 JP 6190368B2
Authority
JP
Japan
Prior art keywords
inh
ivig
combination
administered
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014531244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526541A5 (https=
JP2014526541A (ja
Inventor
ミラン・バスタ
シンジー・チェン
マーク・マットソン
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー, ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ, ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2014526541A publication Critical patent/JP2014526541A/ja
Publication of JP2014526541A5 publication Critical patent/JP2014526541A5/ja
Application granted granted Critical
Publication of JP6190368B2 publication Critical patent/JP6190368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014531244A 2011-09-24 2012-09-21 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 Active JP6190368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
US61/538,832 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (3)

Publication Number Publication Date
JP2014526541A JP2014526541A (ja) 2014-10-06
JP2014526541A5 JP2014526541A5 (https=) 2015-11-05
JP6190368B2 true JP6190368B2 (ja) 2017-08-30

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531244A Active JP6190368B2 (ja) 2011-09-24 2012-09-21 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法

Country Status (9)

Country Link
US (1) US10471142B2 (https=)
EP (1) EP2758076B1 (https=)
JP (1) JP6190368B2 (https=)
KR (1) KR101956585B1 (https=)
CN (1) CN104010656B (https=)
AU (1) AU2012311483B2 (https=)
DK (1) DK2758076T3 (https=)
ES (1) ES2714999T3 (https=)
WO (1) WO2013041677A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
US20180036394A1 (en) * 2015-02-20 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法

Also Published As

Publication number Publication date
KR20140075753A (ko) 2014-06-19
CN104010656B (zh) 2016-02-24
HK1200334A1 (en) 2015-08-07
CA2848510A1 (en) 2013-03-28
US20140234293A1 (en) 2014-08-21
EP2758076B1 (en) 2018-12-12
AU2012311483B2 (en) 2016-03-10
KR101956585B1 (ko) 2019-03-11
JP2014526541A (ja) 2014-10-06
US10471142B2 (en) 2019-11-12
WO2013041677A1 (en) 2013-03-28
ES2714999T3 (es) 2019-05-31
EP2758076A1 (en) 2014-07-30
DK2758076T3 (en) 2019-04-01
CN104010656A (zh) 2014-08-27
AU2012311483A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
JP6190368B2 (ja) 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法
TWI831106B (zh) 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
Ishrat et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats
Lei et al. Growth factors outside the PDGF family drive experimental PVR
Xiaohong et al. CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress
US10925858B2 (en) S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy
NZ759187A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
US20240358721A1 (en) Gasdermin-d inhibitors and uses thereof for treating pulmonary vaso-occlusion
Chen et al. Combination therapy with low-dose IVIG and a C1-esterase inhibitor ameliorates brain damage and functional deficits in experimental ischemic stroke
US20230301967A1 (en) Methods and compositions for the treatment of retinopathy and other ocular diseases
CN104080474A (zh) C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
WO2014170892A1 (en) Inhibition of rip kinases for treating lysosomal storage diseases
US20220340659A1 (en) Activity Modulator
CN116617390A (zh) Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
JP2021522241A5 (https=)
US20230132275A1 (en) Use of cdon inhibitors for the treatment of endothelial dysfunction
WO2023222051A1 (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
Xiao et al. Cathepsin S in the spinal microglia facilitates morphine-induced antinociceptive tolerance in rats
CA3250474A1 (en) TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
RU2773957C2 (ru) Модулятор активности
US20200062855A1 (en) Compositions and methods of promoting wound healing
WO2025113598A9 (zh) 稳定的混合抗体的药物组合物
TW201817426A (zh) 三萜混合物用以治療多發性硬化的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170804

R150 Certificate of patent or registration of utility model

Ref document number: 6190368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250